TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has released the financial results for its fiscal 2007 third quarter, ended June 30, 2007.
During the third quarter of fiscal 2007, the Company's primary focus was on product development of its three late-stage potential blockbuster therapeutics: SinuNase™ for Chronic Sinusitis (CS), Revimmune for refractory multiple sclerosis, and BiovaxID for non-Hodgkin’s lymphoma.
